What’s Ahead for Apricus Biosciences, Inc. (APRI) After Touching Yearly Low?

April 16, 2018 - By Michael Collier

The stock of Apricus Biosciences, Inc. (NASDAQ:APRI) hit a new 52-week low and has $0.27 target or 7.00 % below today’s $0.29 share price. The 6 months bearish chart indicates high risk for the $6.75 million company. The 1-year low was reported on Apr, 16 by Barchart.com. If the $0.27 price target is reached, the company will be worth $472,430 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 31.45% or $0.1321 during the last trading session, reaching $0.2879. About 3.38M shares traded or 128.77% up from the average. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 72.97% since April 16, 2017 and is downtrending. It has underperformed by 84.52% the S&P500.

Analysts await Apricus Biosciences, Inc. (NASDAQ:APRI) to report earnings on May, 10. They expect $-0.10 earnings per share, up 77.27 % or $0.34 from last year’s $-0.44 per share. After $-0.16 actual earnings per share reported by Apricus Biosciences, Inc. for the previous quarter, Wall Street now forecasts -37.50 % EPS growth.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. The company has market cap of $6.75 million. The Company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. It has a 10.66 P/E ratio. The firm also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Apricus Biosciences, Inc. (NASDAQ:APRI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.